FLT3 and acute myeloid leukemia: The sensitive patient-specific PCR targeted either to the FLT3/ITD breakpoint or to the intronic fusion of the various chimeric genes provide potentially a very useful tool not only for backtracking of leukemia but also for the minimal residual disease monitoring in almost 50% of children with AML, where common molecular marker is unavailable (unlike Ig/TCR rearrangements in ALL).